Symbols / BTAI $1.54 +3.36%
BTAI Chart
About
BioXcel Therapeutics, Inc., together with its subsidiary, OnkosXcel Therapeutics LLC, operates as a biopharmaceutical company that utilizes artificial intelligence approaches to develop medicines in neuroscience and immuno-oncology in the United States. The company IGALMI, a sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. It also develops its neuroscience candidate, BXCL501, which is an investigational, proprietary, orally dissolving film formulation of dexmedetomidine in Phase 3 trial for the treatment of agitation associated with bipolar disorders, schizophrenia, and Alzheimer's disease, as well as opioid use disorder, alcohol use disorder with comorbid post-traumatic stress disorder, and acute stress disorder; and its immune-oncology candidate, BXCL701, which is an investigational oral innate immune activator that has completed Phase 1b/2a trial for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors. In addition, the company engages in the development of BXCL502 for the treatment of stress-related neuropsychiatric symptoms in dementia and other stress-related disorders; BXCL503, a drug candidate to target apathy in dementia; and BXCL504, which has the potential to address apathy and aggression in dementia. The company has collaborations with Columbia University, Yale University Medical School, and University of North Carolina for the development of BXCL501. BioXcel Therapeutics, Inc. was incorporated in 2017 and is headquartered in New Haven, Connecticut.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Drug Manufacturers - Spe | Market Cap | 33.68M |
| Enterprise Value | 106.79M | Income | -68.21M | Sales | 752.00K |
| Book/sh | -4.45 | Cash/sh | 1.65 | Dividend Yield | — |
| Payout | 0.00% | Employees | 37 | IPO | — |
| P/E | — | Forward P/E | -0.59 | PEG | — |
| P/S | 44.79 | P/B | -0.35 | P/C | — |
| EV/EBITDA | -2.13 | EV/Sales | 142.01 | Quick Ratio | 0.96 |
| Current Ratio | 1.18 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -9.29 | EPS next Y | -2.63 | EPS Growth | — |
| Revenue Growth | -54.20% | Earnings | 2026-03-26 | ROA | -67.31% |
| ROE | — | ROIC | — | Gross Margin | -28.19% |
| Oper. Margin | -143.20% | Profit Margin | 0.00% | Shs Outstand | 21.87M |
| Shs Float | 19.71M | Short Float | 8.81% | Short Ratio | 5.65 |
| Short Interest | — | 52W High | 8.08 | 52W Low | 1.17 |
| Beta | 0.23 | Avg Volume | 1.38M | Volume | 591.77K |
| Target Price | $14.25 | Recom | Buy | Prev Close | $1.49 |
| Price | $1.54 | Change | 3.36% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$14.25
Mean price target
2. Current target
$1.65
Latest analyst target
3. DCF / Fair value
$-35.62
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.65
Low
$1.00
High
$38.00
Mean
$14.25
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-03-17 | init | Rodman & Renshaw | — → Buy | $17 |
| 2026-03-05 | main | HC Wainwright & Co. | Buy → Buy | $6 |
| 2025-09-15 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2025-09-12 | main | Mizuho | Neutral → Neutral | $4 |
| 2025-08-28 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2025-08-19 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2025-08-15 | main | HC Wainwright & Co. | Buy → Buy | $10 |
| 2025-07-15 | reit | LUCID CAPITAL MARKETS | Buy → Buy | $66 |
| 2025-06-23 | main | HC Wainwright & Co. | Buy → Buy | $8 |
| 2025-03-19 | init | Rodman & Renshaw | — → Buy | $65 |
| 2025-01-30 | main | HC Wainwright & Co. | Buy → Buy | $3 |
| 2025-01-07 | down | B of A Securities | Buy → Underperform | $0 |
| 2025-01-06 | main | Canaccord Genuity | Buy → Buy | $5 |
| 2024-10-21 | main | HC Wainwright & Co. | Buy → Buy | $5 |
| 2024-09-06 | reit | HC Wainwright & Co. | Buy → Buy | $7 |
| 2024-08-30 | main | Canaccord Genuity | Buy → Buy | $7 |
| 2024-08-09 | main | UBS | Neutral → Neutral | $1 |
| 2024-08-08 | main | HC Wainwright & Co. | Buy → Buy | $7 |
| 2024-06-27 | main | Canaccord Genuity | Buy → Buy | $7 |
| 2024-05-10 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
- BioXcel Therapeutics (BTAI) officer converts 68 RSUs into common shares - Stock Titan ue, 17 Mar 2026 00
- BTAI: BioXcel Therapeutics Initiates Coverage with 'Buy' Rating - GuruFocus ue, 17 Mar 2026 13
- BioXcel Therapeutics stock initiated with buy rating at Rodman - Investing.com ue, 17 Mar 2026 13
- How The BioXcel Therapeutics (BTAI) Story Is Shifting With Dilution Risks And Funding Needs - Yahoo Finance hu, 12 Mar 2026 18
- This Ingredion Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Benzinga ue, 17 Mar 2026 12
- BioXcel Therapeutics, Inc. Completes $8 Million Registered Direct Offering of Common Stock and Warrants - Quiver Quantitative Wed, 11 Mar 2026 22
- Drug film BXCL501 eases opioid withdrawal in Columbia University study - Stock Titan hu, 05 Mar 2026 12
- BioXcel stock down despite late-stage trial win (BTAI:NASDAQ) - Seeking Alpha Wed, 27 Aug 2025 07
- Halper Sadeh LLC Encourages BioXcel Therapeutics, Inc. Shareholders to Contact the Firm to Discuss Their Rights - Business Wire hu, 15 Jan 2026 08
- BioXcel Therapeutics, Inc. (BTAI) Reports Q3 Loss, Misses Revenue Estimates - Yahoo Finance Wed, 12 Nov 2025 08
- AI-driven drugmaker BioXcel raises $8M, extends investor warrants - Stock Titan Wed, 11 Mar 2026 20
- BioXcel Therapeutics, Inc. Announces Registered Direct Offering to Raise Approximately $8.0 Million - Quiver Quantitative ue, 10 Mar 2026 18
- Why Are BioXcel Therapeutics Shares Down Friday? - Benzinga Fri, 06 Mar 2026 08
- BTAI Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan Fri, 13 Feb 2026 22
- BioXcel Therapeutics (NASDAQ: BTAI) raises ~$7.3M with 2.48M share offering - Stock Titan Wed, 11 Mar 2026 12
Insider Transactions
| Date | Shares | Url | Text | Insider | Position | Transaction | Start Date | Ownership | Value |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 68 | — | — | STEINHART RICHARD I | Chief Financial Officer | — | 2025-12-15 00:00:00 | D | nan |
| 1 | 383 | — | — | MEHTA VIMAL | Chief Executive Officer | — | 2025-12-15 00:00:00 | D | nan |
| 2 | 68 | — | — | YOCCA FRANK D. PH.D. | Officer | — | 2025-12-15 00:00:00 | D | nan |
| 3 | 68 | — | — | RODRIGUEZ JAVIER | Officer | — | 2025-12-15 00:00:00 | D | nan |
| 4 | 1694 | — | — | MACK DAVID J | Director | — | 2025-10-31 00:00:00 | D | nan |
| 5 | 1694 | — | — | MACK DAVID J | Director | — | 2025-09-30 00:00:00 | D | nan |
| 6 | 68 | — | — | STEINHART RICHARD I | Chief Financial Officer | — | 2025-09-15 00:00:00 | D | nan |
| 7 | 382 | — | — | MEHTA VIMAL | Chief Executive Officer | — | 2025-09-15 00:00:00 | D | nan |
| 8 | 68 | — | — | YOCCA FRANK D. PH.D. | Officer | — | 2025-09-15 00:00:00 | D | nan |
| 9 | 68 | — | — | RODRIGUEZ JAVIER | Officer | — | 2025-09-15 00:00:00 | D | nan |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -41.72M | -161.26M | -157.22M | -106.59M |
| TotalUnusualItems | -2.44M | -4.16M | 0.00 | |
| TotalUnusualItemsExcludingGoodwill | -2.44M | -4.16M | 0.00 | |
| NetIncomeFromContinuingOperationNetMinorityInterest | -59.60M | -179.05M | -165.76M | -106.93M |
| ReconciledDepreciation | 309.00K | 318.00K | 327.00K | 297.00K |
| ReconciledCostOfRevenue | 2.14M | 1.26M | 20.00K | 0.00 |
| EBITDA | -44.16M | -165.42M | -157.22M | -106.59M |
| EBIT | -44.47M | -165.74M | -157.54M | -106.89M |
| NetInterestIncome | -12.53M | -7.67M | -5.68M | 4.00K |
| InterestExpense | 15.13M | 13.31M | 8.21M | 40.00K |
| InterestIncome | 2.60M | 5.65M | 2.53M | 44.00K |
| NormalizedIncome | -57.16M | -174.89M | -165.76M | -106.93M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -59.60M | -179.05M | -165.76M | -106.93M |
| TotalExpenses | 67.07M | 169.00M | 160.02M | 106.94M |
| TotalOperatingIncomeAsReported | -67.25M | -171.78M | -159.65M | -106.94M |
| DilutedAverageShares | 2.54M | 1.82M | 1.75M | 1.65M |
| BasicAverageShares | 2.54M | 1.82M | 1.75M | 1.65M |
| DilutedEPS | -23.51 | -98.40 | -94.72 | -64.80 |
| BasicEPS | -23.51 | -98.40 | -94.72 | -64.80 |
| DilutedNIAvailtoComStockholders | -59.60M | -179.05M | -165.76M | -106.93M |
| NetIncomeCommonStockholders | -59.60M | -179.05M | -165.76M | -106.93M |
| NetIncome | -59.60M | -179.05M | -165.76M | -106.93M |
| NetIncomeIncludingNoncontrollingInterests | -59.60M | -179.05M | -165.76M | -106.93M |
| NetIncomeContinuousOperations | -59.60M | -179.05M | -165.76M | -106.93M |
| PretaxIncome | -59.60M | -179.05M | -165.76M | -106.93M |
| OtherIncomeExpense | 17.73M | -3.77M | -427.00K | |
| OtherNonOperatingIncomeExpenses | 20.17M | 394.00K | -427.00K | |
| SpecialIncomeCharges | -2.44M | -4.16M | 0.00 | |
| RestructuringAndMergernAcquisition | 2.44M | 4.16M | 0.00 | |
| NetNonOperatingInterestIncomeExpense | -12.53M | -7.67M | -5.68M | 4.00K |
| InterestExpenseNonOperating | 15.13M | 13.31M | 8.21M | 40.00K |
| InterestIncomeNonOperating | 2.60M | 5.65M | 2.53M | 44.00K |
| OperatingIncome | -64.80M | -167.62M | -159.65M | -106.94M |
| OperatingExpense | 64.93M | 167.74M | 160.00M | 106.94M |
| ResearchAndDevelopment | 30.43M | 84.33M | 91.24M | 52.71M |
| SellingGeneralAndAdministration | 34.49M | 83.41M | 68.76M | 54.23M |
| SellingAndMarketingExpense | 1.39M | 12.48M | 13.01M | 3.00M |
| GeneralAndAdministrativeExpense | 33.10M | 70.93M | 55.76M | 54.23M |
| OtherGandA | 19.67M | 29.72M | 19.92M | 29.72M |
| InsuranceAndClaims | 1.67M | 1.74M | 2.37M | 2.14M |
| SalariesAndWages | 11.76M | 39.46M | 33.47M | 22.37M |
| GrossProfit | 123.00K | 120.00K | 355.00K | 0.00 |
| CostOfRevenue | 2.14M | 1.26M | 20.00K | 0.00 |
| TotalRevenue | 2.27M | 1.38M | 375.00K | 0.00 |
| OperatingRevenue | 2.27M | 1.38M | 375.00K | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 3.10M | 1.87M | 1.76M | 1.75M |
| ShareIssued | 3.10M | 1.87M | 1.76M | 1.75M |
| NetDebt | 72.65M | 35.38M | ||
| TotalDebt | 102.95M | 101.04M | 93.84M | 1.10M |
| TangibleBookValue | -93.10M | -56.51M | 76.78M | 221.67M |
| InvestedCapital | 9.41M | 44.09M | 169.83M | 221.67M |
| WorkingCapital | 15.16M | 44.88M | 169.97M | 220.15M |
| NetTangibleAssets | -93.10M | -56.51M | 76.78M | 221.67M |
| CapitalLeaseObligations | 439.00K | 440.00K | 786.00K | 1.10M |
| CommonStockEquity | -93.10M | -56.51M | 76.78M | 221.67M |
| TotalCapitalization | 9.41M | 44.09M | 169.83M | 221.67M |
| TotalEquityGrossMinorityInterest | -93.10M | -56.51M | 76.78M | 221.67M |
| StockholdersEquity | -93.10M | -56.51M | 76.78M | 221.67M |
| RetainedEarnings | -650.20M | -590.60M | -411.55M | -245.79M |
| AdditionalPaidInCapital | 557.05M | 534.06M | 488.29M | 467.43M |
| CapitalStock | 49.00K | 30.00K | 28.00K | 28.00K |
| CommonStock | 49.00K | 30.00K | 28.00K | 28.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 131.44M | 130.21M | 129.08M | 17.77M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 109.21M | 102.94M | 96.18M | 1.10M |
| DerivativeProductLiabilities | 6.63M | 1.91M | 2.34M | 0.00 |
| LongTermDebtAndCapitalLeaseObligation | 102.57M | 101.04M | 93.84M | 1.10M |
| LongTermCapitalLeaseObligation | 65.00K | 440.00K | 786.00K | 1.10M |
| LongTermDebt | 102.51M | 100.60M | 93.05M | |
| CurrentLiabilities | 22.23M | 27.27M | 32.90M | 16.67M |
| OtherCurrentLiabilities | 346.00K | 404.00K | 293.00K | |
| CurrentDebtAndCapitalLeaseObligation | 374.00K | 346.00K | 319.00K | 293.00K |
| CurrentCapitalLeaseObligation | 374.00K | 346.00K | 319.00K | 293.00K |
| PensionandOtherPostRetirementBenefitPlansCurrent | 35.00K | 163.00K | 6.37M | 3.97M |
| PayablesAndAccruedExpenses | 21.82M | 26.76M | 26.12M | 12.41M |
| CurrentAccruedExpenses | 5.64M | 12.88M | 15.39M | 7.22M |
| InterestPayable | 0.00 | 736.00K | 3.17M | 0.00 |
| Payables | 16.19M | 13.88M | 10.73M | 5.18M |
| DuetoRelatedPartiesCurrent | 107.00K | 107.00K | 422.00K | 204.00K |
| TotalTaxPayable | 91.00K | 116.00K | 82.00K | 302.00K |
| AccountsPayable | 15.99M | 13.65M | 10.23M | 4.68M |
| TotalAssets | 38.34M | 73.70M | 205.85M | 239.44M |
| TotalNonCurrentAssets | 944.00K | 1.56M | 2.98M | 2.63M |
| OtherNonCurrentAssets | 87.00K | 87.00K | 925.00K | 86.00K |
| NetPPE | 857.00K | 1.47M | 2.06M | 2.54M |
| AccumulatedDepreciation | -1.50M | -1.19M | -885.00K | -602.00K |
| GrossPPE | 2.36M | 2.67M | 2.94M | 3.14M |
| Leases | 1.20M | 1.20M | 1.18M | 1.13M |
| ConstructionInProgress | 0.00 | 24.00K | ||
| OtherProperties | 976.00K | 1.25M | ||
| MachineryFurnitureEquipment | 777.00K | 777.00K | 788.00K | 739.00K |
| BuildingsAndImprovements | 382.00K | 688.00K | 976.00K | |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 37.39M | 72.14M | 202.87M | 236.81M |
| OtherCurrentAssets | 1.44M | 2.08M | 3.84M | 956.00K |
| PrepaidAssets | 5.29M | 2.78M | 3.07M | 2.89M |
| Inventory | 679.00K | 1.99M | 1.99M | 0.00 |
| FinishedGoods | 173.00K | 405.00K | 595.00K | |
| WorkInProcess | 0.00 | 651.00K | 708.00K | |
| RawMaterials | 506.00K | 935.00K | 682.00K | |
| Receivables | 131.00K | 71.00K | 248.00K | 0.00 |
| AccountsReceivable | 131.00K | 71.00K | 248.00K | 0.00 |
| CashCashEquivalentsAndShortTermInvestments | 29.85M | 65.22M | 193.72M | 232.97M |
| CashAndCashEquivalents | 29.85M | 65.22M | 193.72M | 232.97M |
| CashFinancial | 232.97M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -72.03M | -155.03M | -135.48M | -82.60M |
| RepurchaseOfCapitalStock | 0.00 | |||
| RepaymentOfDebt | -2.50M | 0.00 | ||
| IssuanceOfDebt | 0.00 | 98.60M | 0.00 | |
| IssuanceOfCapitalStock | 39.69M | 27.03M | 0.00 | 100.99M |
| CapitalExpenditure | -20.00K | -139.00K | -445.00K | |
| InterestPaidSupplementalData | 7.97M | 7.55M | 2.70M | 40.00K |
| EndCashPosition | 29.85M | 65.22M | 193.72M | 232.97M |
| BeginningCashPosition | 65.22M | 193.72M | 232.97M | 213.12M |
| ChangesInCash | -35.37M | -128.50M | -39.24M | 19.85M |
| FinancingCashFlow | 36.66M | 26.52M | 96.24M | 102.45M |
| CashFlowFromContinuingFinancingActivities | 36.66M | 26.52M | 96.24M | 102.45M |
| NetOtherFinancingCharges | -528.00K | -1.02M | -2.65M | |
| ProceedsFromStockOptionExercised | 0.00 | 508.00K | 283.00K | 1.45M |
| NetCommonStockIssuance | 39.69M | 27.03M | 0.00 | 100.99M |
| CommonStockPayments | 0.00 | |||
| CommonStockIssuance | 39.69M | 27.03M | 0.00 | 100.99M |
| NetIssuancePaymentsOfDebt | -2.50M | 0.00 | 98.60M | 0.00 |
| NetLongTermDebtIssuance | -2.50M | 0.00 | 98.60M | 0.00 |
| LongTermDebtPayments | -2.50M | 0.00 | ||
| LongTermDebtIssuance | 0.00 | 98.60M | 0.00 | |
| InvestingCashFlow | 0.00 | -20.00K | -139.00K | -445.00K |
| CashFlowFromContinuingInvestingActivities | 0.00 | -20.00K | -139.00K | -445.00K |
| NetPPEPurchaseAndSale | 0.00 | -20.00K | -139.00K | -445.00K |
| PurchaseOfPPE | 0.00 | -20.00K | -139.00K | -445.00K |
| OperatingCashFlow | -72.03M | -155.01M | -135.34M | -82.15M |
| CashFlowFromContinuingOperatingActivities | -72.03M | -155.01M | -135.34M | -82.15M |
| ChangeInWorkingCapital | -6.03M | 2.02M | 10.40M | 4.98M |
| ChangeInOtherWorkingCapital | 264.00K | |||
| ChangeInOtherCurrentLiabilities | -346.00K | -319.00K | -293.00K | -237.00K |
| ChangeInOtherCurrentAssets | 271.00K | 264.00K | ||
| ChangeInPayablesAndAccruedExpense | -5.06M | -722.00K | 16.83M | 4.85M |
| ChangeInAccruedExpense | -736.00K | 2.50M | 3.80M | 0.00 |
| ChangeInInterestPayable | -736.00K | 2.50M | 3.80M | 0.00 |
| ChangeInPayable | -4.33M | -3.22M | 13.03M | 4.85M |
| ChangeInAccountPayable | -4.33M | -3.22M | 13.03M | 4.85M |
| ChangeInPrepaidAssets | -1.87M | 2.89M | -3.90M | 103.00K |
| ChangeInInventory | 1.31M | -6.00K | -1.99M | 0.00 |
| ChangeInReceivables | -60.00K | 177.00K | -248.00K | 0.00 |
| ChangesInAccountReceivables | -60.00K | 177.00K | -248.00K | 0.00 |
| OtherNonCashItems | 7.32M | 3.53M | 1.94M | |
| StockBasedCompensation | 6.16M | 18.61M | 17.34M | 19.45M |
| DepreciationAmortizationDepletion | 309.00K | 318.00K | 327.00K | 297.00K |
| DepreciationAndAmortization | 309.00K | 318.00K | 327.00K | 297.00K |
| Depreciation | 309.00K | 318.00K | 327.00K | 297.00K |
| OperatingGainsLosses | -20.18M | -436.00K | 411.00K | 46.00K |
| GainLossOnInvestmentSecurities | -20.18M | -438.00K | 389.00K | |
| GainLossOnSaleOfPPE | 0.00 | 2.00K | 22.00K | 46.00K |
| NetIncomeFromContinuingOperations | -59.60M | -179.05M | -165.76M | -106.93M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for BTAI
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|